Starting July 1, 2026, Medicare beneficiaries in the United States will gain access to GLP-1 receptor agonists—medications primarily used for weight loss—for the first time. These drugs, which include Eli Lilly’s Foundayo, Zepbound KwikPen, and Novo Nordisk’s Wegovy, will be available through a new pilot program known as the Medicare GLP-1 Bridge. Under this initiative, eligible patients will pay a $50 monthly copayment, making these previously expensive medications more accessible to those who need them most. The program is set to last until the end of 2027, after which its continuation depends on either an extension by the Centers for Medicare & Medicaid Services (CMS) or legislative action by Congress.
The Medicare GLP-1 Bridge represents a significant shift in how Medicare covers weight-loss medications. Previously, GLP-1 drugs were only covered for patients with conditions such as diabetes or cardiovascular disease. Now, the program allows coverage for individuals seeking treatment for obesity alone, provided they meet specific clinical criteria. To qualify, patients must have a BMI of at least 35, or a BMI of at least 30 combined with a history of heart failure, uncontrolled hypertension, or chronic kidney disease, or a BMI of at least 27 alongside prediabetes, a previous heart attack or stroke, or symptomatic peripheral artery disease. Those already receiving GLP-1 prescriptions for conditions like Type 2 diabetes or sleep apnea are not eligible for the new program.
Eligible participants must be enrolled in Medicare Part D and part of an approved plan. Their healthcare providers must submit a prior authorization request, demonstrating that the patient is being prescribed a GLP-1 specifically for weight loss. This approval process ensures that only those meeting strict clinical guidelines benefit from the program. While the $50 monthly copay is relatively low compared to the usual out-of-pocket expenses, it does not contribute toward the beneficiary’s annual deductible or out-of-pocket maximum. Additionally, patients are not permitted to use manufacturer coupons or discounts to reduce the cost further.
The program operates outside the standard Medicare Part D framework, meaning the $50 copay is collected directly by pharmacies, while a central processing entity handles payments to the pharmacies. According to CMS, the manufacturers will provide eligible GLP-1 drugs at a net price of $245 per monthly supply. This arrangement effectively shifts some of the financial burden onto taxpayers, as the government subsidizes the difference between the $245 wholesale price and the $50 copay paid by the patient.
While the Medicare GLP-1 Bridge offers immediate relief for patients struggling with obesity and its associated health risks, experts caution that it is not a long-term solution. Juliette Cubanski of the Kaiser Family Foundation noted that the future of GLP-1 coverage remains uncertain beyond 2027. Without legislative changes or an extension by CMS, beneficiaries could face a return to high out-of-pocket costs. Some analysts argue that the program highlights the potential for market-driven solutions to reduce drug prices, as seen in the direct-to-consumer market where prices have dropped significantly over the past few years due to increased competition and reduced third-party costs.
Critics warn that viewing the Medicare GLP-1 Bridge as a model for government price control could discourage investment in future medical innovations. They emphasize that sustained affordability comes from fostering competition among pharmaceutical companies and ensuring direct access for consumers. As the program moves forward, its success will depend on maintaining this balance between accessibility and encouraging continued innovation in the field of obesity treatment.
4 reports
STAT NewsIndependentCenteryesterdayA U.S. judge has blocked a Colorado state panel from imposing a price cap on Amgen's drug Enbrel, ruling that the company would likely suffer significant harm. This decision halts a pioneering initiative by the Colorado Prescription Drug Affordability Board, established four years ago to address rising medication costs by setting upper payment limits for select drugs. Separately, a new Medicare program will allow millions of Americans aged 65 and older to access obesity medications like Novo Nordisk's Wegovy and Eli Lilly's Foundayo and Zepbound at a reduced monthly cost of $50. This marks a notable change from recent years, during which patients often faced high out-of-pocket expenses for these treatments.
Bias read (Center): The article presents both developments neutrally, providing factual information about judicial decisions and policy changes without overtly favoring any political perspective. It does not employ loaded language or one-sided sourcing.
STAT NewsIndependentLeft4 days ago STAT+: The loophole in Trump’s obesity drug deal with Eli Lilly and Novo NordiskThe article discusses a loophole in the Trump administration's agreement with drugmakers Eli Lilly and Novo Nordisk regarding GLP-1 drugs. The deal aimed to secure lower prices in exchange for increased sales volume, but the companies achieved higher sales without lowering prices. The administration negotiated a $245 monthly price for Medicare and Medicaid, intended to apply to all GLP-1s, including those for obesity. However, this price was conditional on private Medicare insurers covering the drugs for all uses with a $50 copay. This condition was not publicly disclosed, but both companies confirmed it to STAT. The article highlights concerns about transparency and potential impacts on patient access.
Bias read (Left): The article frames the situation as a failure of transparency and accountability by the Trump administration, highlighting the lack of disclosure regarding the conditions of the drug pricing deal. It emphasizes the potential negative impact on patients and suggests a critique of the administration's
The HillIndependentCenter5 days agoThe article discusses the Medicare GLP-1 Bridge program introduced by Dr. Oz, which allows eligible Medicare Part D beneficiaries to access certain GLP-1 medications for $50 per month starting July 1, 2025, through December 31, 2027. The program includes drugs like Wegovy, Zepbound, and Foundayo for weight loss. While the initiative is praised for providing affordable access to obesity treatments, the article clarifies that it is a temporary subsidy funded by taxpayers rather than a permanent price control measure. It argues that the low cost is due to market-driven reductions in prices, driven by competition and direct-to-consumer sales models. Examples include Lilly lowering prices for Zepbound and NovoCare Pharmacy offering Wegovy at discounted rates. The article warns against misinterpreting the program as evidence that government price controls are effective, emphasizing that market forces and direct patient access are the true drivers of affordability.
Bias read (Center): While the article critiques government intervention and advocates for market-based solutions, it does not overtly favor one political ideology over another. It presents both the benefits of the Medicare GLP-1 Bridge and the limitations of government price controls without clear ideological slant. It
STAT NewsIndependentCenter10 days ago STAT+: Exclusive: Mystery man gets experimental GLP-1The article discusses a case where a single individual was granted compassionate-use access to an experimental GLP-1 drug developed by Eli Lilly for obesity treatment. The focus is on the unique circumstances surrounding this access, which appears to be an exclusive report covered in STAT+'s subscription-based content. The article highlights the broader implications of such decisions regarding experimental drugs and their approval processes.
Bias read (Center): The article focuses on a specific medical case involving experimental drug access, which is primarily a health-related issue rather than a politically charged topic. There is no indication of framing that favors one side over another, and the content does not involve significant political debate or,
★
Keep the news honest.
ObjectiveNews is reader-funded and ad-free — we show you the bias instead of hiding it. Support independent journalism for €5/month.
Become a Supporter
United States
